While you are here...
A unique insight into BioInnovation Institute’s 2022 Journey
We proudly present BioInnovation Institute’s (BII) 2022 impact report. This report highlights the impact and achievements of our organization over the past year in advancing groundbreaking research and entrepreneurship in the life sciences. The report showcases the changes we have made to our catalyst platform, the accomplishments of our expanding and thriving portfolio, and the steps we have taken to broaden our outreach, community, and collaborations. The stories and data in the report confirm how BII plays a crucial role in helping early-stage start-ups turn pioneering science into solutions that improve human and planetary health around the world.
We want to say a huge thank you to all our partners, stakeholders, and the broader ecosystem, who have all contributed to our positive development in 2022. We hope this report will enlighten you on BII’s positive impact in the life sciences sector in 2022 and inspire your continued support for our mission.
“In the past year, BII has grown and expanded our offer to innovative entrepreneurs in the life science community, and the impact on the ecosystem is clear.
Throughout this report, you will find examples and read stories about our endeavors, but I would like to point out some of the achievements that I am particularly excited about.
In 2022, BII welcomed more start-ups and projects than ever before. With a 20 percent increase from 2021, we have now accepted a total of 80 projects and start-ups into our programs, and accumulatively our portfolio companies have raised EUR 240 million in additional funding since BII’s inauguration. In 2022 alone, they raised EUR 90 million.
With the success of our portfolio companies, BII is beginning to significantly impact the life science ecosystem in Denmark by creating new jobs and attracting the interest of world leaders within life science philanthropy and industry. In 2022, we have, among many others, welcomed corporate-sponsored projects from Novo Nordisk and arranged many activities to strengthen the ecosystem within the area of women’s health.
The academic community has also moved closer, as we have launched the Bio Studio program. With this new program, we strive to build a leading life science-company creation facility in Europe. We have already welcomed projects from prestigious institutions such as EMBL, Imperial College London, and the University of Washington, and when fully implemented, Bio Studio will run 15-20 top-level venture creation projects, all run by experienced entrepreneurs in residence.
I am proud of the progress and impact we have achieved in 2022, and I am thankful for your continued support and partnership. I believe that together, we can drive the development of new solutions and ultimately, positively impact the societal challenges in human and planetary health around the world.”
Chief Executive Officer, BII
Transforming a catalyst platform
BII is developing a platform that accelerates life science innovation from the very early stages and toward series A investments. We continuously test, evaluate and shape our programs, and in 2022 we presented Venture House, which targets alumni from the early-stage program Venture Lab. In the Venture House program, the companies will further mature and de-risk to attract substantial funding.
In addition to the two Venture programs, BII supports world-leading scientists in translating academic research in the Bio Studio program. BII Residence is for life science companies that have raised substantial funding and are looking to join an entrepreneurial environment and expand their network.
Expanding our thriving portfolio
BII’s funding, business development support, lab and office infrastructure, and global network have allowed our portfolio to thrive and raise EUR 90 million in additional funding in 2022. In 2022, we welcomed 20 percent more start-ups and projects into our programs than in 2021, and our portfolio remains strong within both human and planetary health.
Broadening outreach, community & collaborations
BII is continuously building partnerships and collaborations with corporates and companies, universities and hospitals, investors, and experts to create a strong foundation and community for our portfolio. This year, we have, among others, partnered with Novo Nordisk and Novozymes, and we have awarded the very first BII & Science Prize for Innovation in collaboration with the scientific journal Science.
The support from the Bill & Melinda Gates Foundation has also accelerated existing efforts, and in 2022, BII introduced the Women’s Health Innovation Panel to help bring forward innovation in Women’s Health.
Previous Impact Reports
Do you want to know about BII’s activities and societal impact in previous years? Check out the impact reports since BII spun out as an independent foundation in 2021 below.